Novel indication for bioabsorbable scaffolds in metal allergy

Niket Patel*, MBBS, BSc, MRCP; Anthony Mechery, MBBS, MD, DM, MRCP; George Kassimis, MD, PhD; Adrian P. Banning, MBBS, MD, FRCP; Rajesh Kharbanda, MBChB, PhD, MRCP

Oxford University Hospitals, Oxford, United Kingdom

A 74-year-old female with exertional breathlessness and a metal allergy underwent angiography following positive stress echocardiography. This demonstrated severe calcific disease of the left anterior descending artery (LAD) (Figure 1A). Percutaneous intervention (PCI) was offered after the failure of medical therapy.

Patch testing confirmed allergy to nickel and cobalt. Most stent platforms contain alloys that include nickel **(Table 1)**, which may contribute to restenosis in this context.

Balloon predilation was unsuccessful (Figure 1B). Therefore, rotablation with a 1.5 mm burr (Boston Scientific, Natick, MA, USA) was performed. After further predilation (Figure 1C) and QCA, overlapping 3×28 mm and 3.5×28 mm ABSORB Revision

1.1 bioabsorbable scaffolds (BVS) (Abbott Vascular, Santa Clara, CA, USA) (Figure 1C) were implanted. Postdilation with a noncompliant 3.25 mm balloon was performed (Figure 1D). The patient was symptom free at six-month review.

Although nickel allergy is not a conventional contraindication to stenting, bioabsorbable scaffolds such as the poly-L-lactide Abbott BVS now provide an alternative interventional strategy to metallic stents in this situation. Additionally, this case exemplifies the use of this technology in complex lesions.

Conflict of interest statement

The authors have no conflicts of interest to declare.



Figure 1. *A)* Calcified mid-LAD lesion. B) Unsuccessful predilation (significant wasting). C) Post-rotablation lesion expansion. D) Result following two overlapping Abbott BVS.

Platform/ Company	Chromium	Cobalt	Platinum	Nickel	Iron	Tungsten	Molybdenum	Manganese
Element/Boston Scientific	18%	-	33%	9%	37%	-	2.60%	0.05%
Multi-Link/Abbott	20%	55%	-	10%	-	15%	-	-
Driver/Medtronic	20%	35%	-	35%	-	-	10%	-

Table 1. Composition of three commonly used stent platforms.

**Corresponding author: Oxford University Hospitals, Headley Way, Oxford, OX3 9DU, United Kingdom. E-mail: niket.patel@ndm.ox.ac.uk*